ConductScience.org, home
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
API referenceFor AI assistants

Trial · NCT03258593

Participant flow48

How many started, completed or left each group, period by period.

1 to 20 of 48

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Run-In Induction PhaseSTARTEDRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg12
Run-In Induction PhaseSTARTEDExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg0
Run-In Induction PhaseSTARTEDLevel 1, Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mg0
Run-In Induction PhaseSTARTEDArm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)0
Run-In Induction PhaseCOMPLETEDRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg12
Run-In Induction PhaseCOMPLETEDExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg0
Run-In Induction PhaseCOMPLETEDLevel 1, Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mg0
Run-In Induction PhaseCOMPLETEDArm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)0
Run-In Induction PhaseNOT COMPLETEDRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg0
Run-In Induction PhaseNOT COMPLETEDExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg0
Run-In Induction PhaseNOT COMPLETEDLevel 1, Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mg0
Run-In Induction PhaseNOT COMPLETEDArm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)0
Run-In Maintenance PhaseSTARTEDRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg12
Run-In Maintenance PhaseSTARTEDExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg0
Run-In Maintenance PhaseSTARTEDLevel 1, Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mg0
Run-In Maintenance PhaseSTARTEDArm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)0
Run-In Maintenance PhaseCOMPLETEDRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg5
Run-In Maintenance PhaseCOMPLETEDExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg0
Run-In Maintenance PhaseCOMPLETEDLevel 1, Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mg0
Run-In Maintenance PhaseCOMPLETEDArm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03258593/flow

API referenceFor AI assistants